Introduction {#sec1}
============

Amino acids (AAs) are among a handful of paramount molecules involved in virtually all aspects of the phenomenon of life. Quite naturally, they played a significant role in organic, bioorganic, medicinal, and pharmaceutical chemistry from the earliest days of modern healthcare and life sciences.^[@ref1]^ In particular, the use of tailor-made^[@ref2]^ AAs in the design of peptides/peptidomimetics with restricted number of conformations and precise positioning of the side-chains in the χ-space^[@ref3]^ is a well-established paradigm in the modern pharmaceutical industry.^[@ref1],[@ref4],[@ref5]^ Quite interestingly, one of the emerging areas of tailor-made AA application is the biological containment strategy of the produced genetically modified organisms.^[@ref6]^ Accordingly, the current interest in the asymmetric synthesis of tailor-made AAs^[@ref7]^ and their analogues, such as amino sulfonic,^[@ref8]^ phosphonic,^[@ref9]^ and fluorine-containing^[@ref10]^ acids, is at an all-time high, targeting novel structural motifs, functions, and properties. Consistent with our continuous interest in asymmetric synthesis of various tailor-made AAs, for example, fluorine-^[@ref11]^ and phosphorus-containing,^[@ref12]^ sterically constrained,^[@ref13]^ and their nonlinear chiroptical properties, such as self-disproportionation of enantiomers,^[@ref14]^ we were actively developing the Ni(II) complex chemistry of AA Schiff bases^[@cit4d],[@cit7d],[@cit7e]^ as a general approach for the preparation of tailor-made AAs ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![General Approach for the Asymmetric Synthesis of AAs via Ni(II) Complexes of Schiff Bases](ao-2018-01424a_0001){#sch1}

As shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, trichloro-substituted ligand (*S*)- or (*R*)-**1**, currently the most frequently used source of recyclable chirality in this method,^[@ref15]^ is reacted with glycine and a source of Ni(II) ions to produce the Schiff base complex **2**.^[@ref16]^ The square-planar Ni(II) complex **2** serves as a versatile chiral nucleophilic glycine equivalent to afford products **3** by the reactions with various electrophilic reagents. Most commonly used reaction types include, for example, alkyl halide alkylations,^[@ref17]^ Michael,^[@ref18]^ aldol,^[@ref19]^ and Mannich^[@ref20]^ addition reactions. Intermediate products **3** can be conveniently disassembled to release target AAs **4--10** and to recycle chiral tridentate ligand **1**. This method can be used for the preparation of general type α-AAs **4**, β-functionalized/substituted derivatives **5**, sym-**6**,^[@ref21]^ or chiral quaternary **7**([@ref22]) α-AAs, in particular, (1*R*,2*S*)-1-amino-2-vinylcyclopropane-1-carboxylic acid **8**([@ref23]) and bis-α-AAs of type **9**.^[@ref24]^ Moreover, the major advantage of this method over other well-developed general approaches^[@cit7b],[@cit7c],[@ref25]^ is its exceptionally successful application for kinetic resolution of unprotected α- and β-AAs of types **4**([@ref26]) and **10**,^[@ref27]^ respectively. This latter application was shown to be competitive with traditionally economically attractive enzymatic approaches.^[@ref28]^ Most recently, using the modular approach^[@ref29]^ for the design of chiral tridentate ligands, we developed a series of ligands featuring free N--H functionality and multiple stereogenic centers.^[@ref30]^ In particular, the adamantyl-containing derivative **11** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}) was found to possess some remarkable physicochemical properties for the development of second-order asymmetric transformation (SOAT) approach for the general synthesis of α-AAs.^[@ref31]^

![Applications of (*S*)-Rimantadine-Derived Ligand **11**; Previous Work on SOAT of Racemic α-AAs and This Work Dealing with Tandem Alkylation--SOAT, for General Asymmetric Synthesis of α-AAs](ao-2018-01424a_0002){#sch2}

As presented in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}, in the previous work, we demonstrated that the newly designed ligand **11** readily reacts with racemic α-AAs **12** to produce a mixture of four theoretically possible diastereomeric products.^[@ref31]^ However, because of the extreme lipophilicity of the adamantyl moiety,^[@ref32]^ one of the diastereomers, (*S*~C~,*R*~N~,*R*~C~)-configured **13**, precipitates from the methanol or aqueous methanol solution, thus driving the equilibrium of all other diastereomers to the one major reaction product. As the next logical step in the advancement of this methodology, we now report a tandem alkylation--SOAT protocol, which includes synthesis of glycine Schiff base Ni(II) complex **14** and its alkylation under phase-transfer catalysis (PTC) conditions followed by SOAT via equilibration/precipitation of major products **15**.

Results and Discussion {#sec2}
======================

Unlike the asymmetric synthesis, where the major product is a result of preferential stereochemical interactions, which can be comprehended, predicted, and rationally designed, the SOAT is essentially a serendipitous approach resulting from rather complex and multifactorial interplay of numerous chemical/steric/physical properties.^[@ref33]^ Nevertheless, success in developing a SOAT process using ligand **11** was predicated on the idea of "extreme" lipophilic properties^[@ref32]^ of the corresponding rimantadine-containing Ni(II) complexes.^[@ref31]^ Drawing from the previous results, we decided to extend the synthetic versatility of this approach by preparing the required diastereomeric complexes not via the reactions of ligand **11** with racemates of the target α-AAs but via homologation of the intermediate glycine derivative. To this end, we focused on the synthesis of required glycine complexes **14** ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

![Optimized Conditions for the Preparation of the Requisite Ni(II) Complexes of Glycine (*S*~C~,*R*~N~)-**14** and (*S*~C~,*S*~N~)-**14**](ao-2018-01424a_0003){#sch3}

After some extensive experimentation, we found that the application of Na~2~CO~3~ as a base, in combination with catalytic amounts of *n*-Bu~4~NI, provides for the most practical preparation of the target glycine complexes (*S*~C~,*R*~N~)-**14** and (*S*~C~,*S*~N~)-**14**, in about 3:1 ratio. Under these conditions, using only 10% excess of glycine and the Ni(II) source allowed for the complete conversion of the starting ligand (*S*)-**11** to products **14**, isolated with quantitative chemical yield. Clean preparation of glycine complexes **14** was very important part of the project allowing us to avoid any unnecessary purification of the intermediate derivatives. Having achieved virtually byproduct-less synthesis of glycine complexes **14**, we focused on the next alkylation step. On the basis of the previous research,^[@cit4d]^ we selected PTC conditions^[@ref34]^ allowing for very mild homologation of the glycine moiety with usually excellent chemical yields. The results obtained are summarized in [Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}.

![Alkylation of Ni(II) Complexes of Glycine (*S*~C~,*R*~N~)-**14** and (*S*~C~,*S*~N~)-**14** under PTC Conditions; Equilibration of Diastereomeric Complexes **17--19** and **15** and Precipitation of the Final Major Product (*S*~C~,*R*~N~,*R*~C~)-**15**](ao-2018-01424a_0004){#sch4}

As a model experiment, we selected the alkylation reaction using *m*-bromobenzyl bromide **16** ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). In this case, the expected product **15a** was previously obtained using the reaction of racemic AA with ligand (*S*)-**11**,^[@ref31]^ thus facilitating the identification and stereochemical assignments. Starting glycine complexes **14** were used as obtained, without any purification, as a 3:1 mixture of (*S*~C~,*R*~N~)-**14** and (*S*~C~,*S*~N~)-**14** diastereomers. We found that using 1,2-dichloroethane as an organic solvent, 30% aqueous NaOH as a base, and 25 mol % of *n*-Bu~4~NI as a phase-transfer catalyst, virtually complete consumption of starting glycine complexes **14** can be achieved in about 10 min of the reaction time. Analysis of the reaction mixture by thin-layer chromatography (TLC) showed expected alkylation products **15a** as a major (\>50%) product and **17a--19a** as minor products. The stereogenic nitrogen and AA α-carbon atoms in compounds **15a** and **17a--19a** are configurationally unstable. Therefore, under the basic conditions, all four diastereomers undergo rapid epimerization and interconversion via stepwise inversion of either nitrogen or α-carbon or both atoms. Nonetheless, diastereomeric products **15a** and **17a--19a** are compounds of different chemical properties, in particular, the solubility in a given solvent, providing the opportunity for a SOAT process. Indeed, the major diastereomer (*S*~C~,*R*~N~,*R*~C~)-**15a** was found to gradually precipitate from the reaction mixture, leading to a progressive transformation of more soluble **17a--19a** to the crystalline precipitate of compound **15a**. Thus, after about 1 h of stirring at room temperature, the reaction mixture was filtered affording diastereomerically pure (*S*~C~,*R*~N~,*R*~C~)-**15a** with 92.4% yield.

This tandem alkylation--SOAT protocol was found to be of general application for the preparation of various phenylalanine-type tailor-made α-AAs. For example, the derivatives of *p*-bromo- (**15b**), *p*-chloro- (**15c**), *p*-trifluoromethyl- (**15d**), *p*-iodo- (**15e**), and *p*-nitro-substituted (**15f**) phenylalanines were readily prepared in diastereomerically pure form under the same conditions using filtration as the final isolation procedure. Of particular interest is the preparation of naphthylalanine derivative (*S*~C~,*R*~N~,*R*~C~)-**15g**, which was isolated with respectable chemical yield. In the case of compounds **15c**,**e**, and **f**, the application of the standard conditions gave relatively lower isolated yields of ∼50--56%. In this regard, we would like to emphasize that relatively modest isolated yields are the result of incomplete precipitation of the major diastereomer from the reaction mixture. Furthermore, it should be noted that under the SOAT conditions, the isolated yield depends on a physicochemical property which can be conditioned by optimizing the solvent system for each particular case.^[@ref33]^ For instance, a gradual addition of water to the reaction mixture leads to a lower solubility of products allowing increasing precipitation of the target products. This possibility was demonstrated on the example of product **15f**, yield of which was improved from 56.5 to 86.5% by adding about 20% of water to the reaction mixture (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01424/suppl_file/ao8b01424_si_001.pdf)). It should be noted, however, that the diastereomeric purity of thus prepared complex **15f** was 93.2% de. On the other hand, attempts to use this tandem procedure for the preparation of α-AA-containing alkyl side-chains were unsuccessful. The major problem we encountered was low reactivity of alkyl halides under the PTC conditions.

Diastereomerically pure Ni(II) complexes **15** can be readily disassembled to release the target AAs or their protected derivatives.^[@cit4d]^ For example, diastereomer (*S*~C~,*R*~N~,*R*~C~)-**15a** was treated with 3 N HCl in methanol to produce *m*-bromo-phenylalanine (*R*)-**20** and chiral ligand (*S*)-**11** ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}). The latter, configurationally uncompromised, was almost quantitatively recovered and reused for continuous synthesis of other AAs.

![Disassembly of Diastereomerically Pure (*S*~C~,*R*~N~,*R*~C~)-**15a**; Isolation of Target Fmoc-Derivative of AA (*R*)-**21** and Recycling of Chiral Ligand (*S*)-**11**](ao-2018-01424a_0005){#sch5}

AA (*R*)-**20** was not isolated in analytically pure form but transformed in situ to the corresponding Fmoc derivative (*R*)-**21**. The standard protection protocol with application of *N*-(9-fluorenylmethoxycarbonyloxy)succinimide (Fmoc-OSu) was used, with an exception that ethylenediaminetetraacetic acid (EDTA) was added to chelate the Ni(II) ions.

In another example, presented in [Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}, we demonstrate the isolation of free *p*-nitro-phenylalanine (*R*)-**23**. Thus, after the disassembly of diastereomerically pure Ni(II) complex (*S*~C~,*R*~N~,*R*~C~)-**15f** in methanol under the action of 3 N HCl, AA (*R*)-**23** was isolated by precipitation at the isoelectric point (pH 5.5) in the presence of EDTA to chelate the Ni(II) ions. For the further use of this tailor-made AA in our peptide-related projects, we also prepared Fmoc-protected derivative (*R*)-**24**, similar to the preparation of *m*-bromo-phenylalanine (*R*)-**21** ([Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}).

![Disassembly of Diastereomerically Pure (*S*~C~,*R*~N~,*R*~C~)-**15f**; Isolation of Target-Free AA (*R*)-**23** and Its Fmoc Derivative (*R*)-**24**, as Well as the Recycling of Chiral Ligand (*S*)-**11**](ao-2018-01424a_0006){#sch6}

Conclusions {#sec3}
===========

We demonstrate that Ni(II) complexes (*S*~C~,*R*~N~)- and (*S*~C~,*S*~N~)-**14**, derived from glycine Schiff base and (*S*)-rimantadine, can be regioselectivity alkylated on the glycine residue under the PTC conditions affording a mixture of up to four diastereomeric products. Without purification, the alkylated products can be submitted to the SOAT conditions allowing a transformation of the diastereomeric mixture to single precipitated stereoisomer **15** of (S~C~,R~N~,R~C~) absolute configuration. The operational convenience and chromatography-free experimental procedures render this method of potentially high synthetic value for the preparation of phenylalanine-type tailor-made α-AAs.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

All reagents and solvents were used as received. The reaction mixture was magnetically stirred and monitored with the aid of TLC on precoated silica gel plates, and visualization was carried out using UV light and ninhydrin. Flash chromatography was performed with the indicated solvents on silica gel (particle size 0.040--0.063 mm). Yields reported are for isolated, spectroscopically pure compounds. ^1^H and ^13^C spectra were recorded on a 300 MHz Brüker instrument. Chemical shifts are given in ppm (δ), referenced to the residual proton resonances of the solvents. Coupling constants (*J*) are given in Hz. The letters s, d, t, q, m, and br stand for singlet, doublet, triplet, quartet, multiplet, and broad, respectively. High-resolution mass spectra (HRMS) were recorded using an ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry system in the ESI mode.

Procedure for the Preparation of Ni(II) Complexes by Reaction of Ligand (*S*)-**11** with Glycine {#sec4.2}
-------------------------------------------------------------------------------------------------

To a mixture of ligand (*S*)-**11** (1.0 g, 2.22 mmol), nickel(II) nitrate hexahydrate (0.71 g, 2.44 mmol), glycine (0.18 g, 2.44 mmol), tetrabutylammonium iodide (0.08 g, 10 mol %), and methanol (40 mL) was added sodium carbonate (1.18 g, 11.1 mmol), and the reaction mixture was stirred at reflux for 2 h. After the ligand (*S*)-**11** was consumed, the reaction was quenched by pouring icy 5% aqueous acetic acid (200 mL) to give a precipitate. The precipitate was filtrated, washed with 5% aqueous acetic acid, and dried in vacuo at 50 °C overnight to afford the diastereomixture of Ni(II) complex (*S*~C~,*R*~N~)-**14** and (*S*~C~,*S*~N~)-**14**. A 3:1 ratio mixture of two diastereomers was obtained. The spectral data were reported in our previous literature.

General Procedure for the Preparation of Ni(II) Complexes via Tandem Alkylation of Ni(II) Complexes of Glycine (*S*~C~,*R*~N~)-**14** and (*S*~C~,*S*~N~)-**14** {#sec4.3}
----------------------------------------------------------------------------------------------------------------------------------------------------------------

To a solution of Ni(II) complexes of glycine (*S*~C~,*R*~N~)-**14** and (*S*~C~,*S*~N~)-**14** (1 equiv) in 1,2-dichloroethane (8 volumes), 30% aqueous sodium hydroxide solution (40 equiv) was added followed by tetrabutylammonium iodide (25 mol %) and the corresponding alkyl halide (1.1 equiv). After stirring at room temperature (rt) for 10--30 min, the reaction mixture was diluted with water and extracted with dichloromethane; then, the organic layer was evaporated to dryness. The obtained residue and potassium carbonate (4 equiv) were stirred in methanol (40 volumes) at reflux for 1 h. After the reaction, several amounts of water were dropped to the mixture to give a precipitate. The precipitate was filtrated, washed with aqueous methanol, and dried in vacuo at 60 °C overnight to afford the corresponding Ni(II) complex.

Ni(II)/(*S*)-**11**/(*R*)-2-Amino-3-(3-bromophenyl)propanoic Acid Schiff Base Complex (*S*~C~,*R*~N~,*R*~C~)-**15a** {#sec4.4}
--------------------------------------------------------------------------------------------------------------------

Yield: 92.4%. The spectral data were reported in our previous literature.

Ni(II)/(*S*)-**11**/(*R*)-2-Amino-3-(4-bromophenyl)propanoic Acid Schiff Base Complex (*S*~C~,*R*~N~,*R*~C~)-**15b** {#sec4.5}
--------------------------------------------------------------------------------------------------------------------

Yield: 79.3%. \[α\]~D~^25^ −2511 (*c* 0.050, CHCl~3~). ^1^H NMR (300 MHz, CDCl~3~): δ 1.38 (d, *J* = 7.1 Hz, 3H), 1.34--1.46 (m, 6H), 1.58--1.80 (m, 6H), 2.04 (s, 3H), 2.39 (br, 1H), 2.48 (q, *J* = 7.1 Hz, 1H), 2.73 (dd, *J* = 5.1, 13.5 Hz, 1H), 3.07 (dd, *J* = 2.5, 13.5 Hz, 1H), 3.12--3.20 (m, 2H), 4.34 (dd, *J* = 3.0, 4.0 Hz, 1H), 6.76 (d, *J* = 2.1 Hz, 1H), 7.08--7.15 (m, 1H), 7.26--7.34 (m, 2H), 7.44 (d, *J* = 8.1 Hz, 2H), 7.57--7.67 (m, 3H), 7.78 (d, *J* = 8.1 Hz, 2H), 8.49 (d, *J* = 9.2 Hz, 1H). ^13^C NMR (75 MHz, CDCl~3~): δ 10.2, 28.5, 36.8, 36.9, 39.1, 39.8, 50.9, 63.0, 72.9, 122.1, 125.7, 126.2, 127.7, 127.7, 128.7, 129.8, 130.0, 130.9, 132.0, 132.7, 132.9, 133.3, 133.9, 136.0, 142.2, 169.8, 177.8, 179.6. HRMS: calcd for C~36~H~38~BrClN~3~NiO~3~ \[M + H\]^+^, 732.1139; found, 732.1152.

Ni(II)/(*S*)-**11**/(*R*)-2-Amino-3-(4-chlorophenyl)propanoic Acid Schiff Base Complex (*S*~C~,*R*~N~,*R*~C~)-**15c** {#sec4.6}
---------------------------------------------------------------------------------------------------------------------

Yield: 50.8%. \[α\]~D~^25^ −2886 (*c* 0.045, CHCl~3~). ^1^H NMR (300 MHz, CDCl~3~): δ 1.28 (d, *J* = 7.1 Hz, 3H), 1.23--1.35 (m, 6H), 1.46--1.69 (m, 6H), 1.93 (s, 3H), 2.26--2.34 (m, 1H), 2.39 (q, *J* = 7.1 Hz, 1H), 2.64 (dd, *J* = 5.1, 13.5 Hz, 1H), 2.94--3.07 (m, 3H), 4.23 (dd, *J* = 3.2, 5.0 Hz, 1H), 6.66 (d, *J* = 2.5 Hz, 1H), 6.98--7.03 (m, 1H), 7.16--7.23 (m, 2H), 7.37 (d, *J* = 8.4 Hz, 2H), 7.48--7.55 (m, 5H), 8.38 (d, *J* = 9.2 Hz, 1H). ^13^C NMR (75 MHz, CDCl~3~): δ 9.8, 28.0, 36.3, 36.5, 38.7, 39.3, 50.4, 62.7, 72.4, 125.2, 125.8, 127.2, 127.3, 128.2, 128.6, 129.4, 129.6, 130.4, 132.3, 132.5, 132.9, 133.1, 133.6, 135.0, 141.7, 169.4, 177.5, 179.1. HRMS: calcd for C~36~H~38~Cl~2~N~3~NiO~3~ \[M + H\]^+^, 688.1644; found, 688.1639.

Ni(II)/(*S*)-**11**/(*R*)-2-Amino-3-(4-trifluorophenyl)propanoic Acid Schiff Base Complex (*S*~C~,*R*~N~,*R*~C~)-**15d** {#sec4.7}
------------------------------------------------------------------------------------------------------------------------

Yield: 73.4%. \[α\]~D~^25^ −2019 (*c* 0.054, CHCl~3~). ^1^H NMR (300 MHz, CDCl~3~): δ 1.27 (d, *J* = 7.1 Hz, 3H), 1.16--1.33 (m, 6H), 1.42--1.68 (m, 6H), 1.91 (s, 3H), 2.25 (d, *J* = 6.2 Hz, 1H), 2.44 (q, *J* = 7.0 Hz, 1H), 2.75 (dd, *J* = 5.1, 13.5 Hz, 1H), 2.85--3.11 (m, 3H), 4.21--4.31 (m, 1H), 6.67 (d, *J* = 2.3 Hz, 1H), 6.96--7.05 (m, 1H), 7.14--7.27 (m, 2H), 7.44--7.58 (m, 5H), 7.78 (d, *J* = 7.9 Hz, 2H), 8.42 (d, *J* = 9.2 Hz, 1H). ^13^C NMR (75 MHz, CDCl~3~): δ 9.6, 28.0, 36.3, 36.4, 38.6, 39.8, 50.4, 63.0, 72.1, 124.2 (q, *J* = 272.4 Hz), 125.1, 125.3 (q, *J* = 3.7 Hz), 125.8, 127.3, 127.4, 128.2, 129.4, 129.6, 130.1 (q, *J* = 32.3 Hz), 130.5, 131.9, 132.4, 132.7, 132.9, 140.7 (q, *J* = 1.4 Hz), 141.8, 169.8, 177.5, 179.0. HRMS: calcd for C~37~H~38~ClF~3~N~3~NiO~3~ \[M + H\]^+^, 722.1907; found, 722.1897.

Ni(II)/(*S*)-**11**/(*R*)-2-Amino-3-(4-iodephenyl)propanoic Acid Schiff Base Complex (*S*~C~,*R*~N~,*R*~C~)-**15e** {#sec4.8}
-------------------------------------------------------------------------------------------------------------------

Yield: 53.5%. \[α\]~D~^25^ −2558 (*c* 0.050, CHCl~3~). ^1^H NMR (300 MHz, CDCl~3~): δ 1.28 (d, *J* = 7.3 Hz, 3H), 1.25--1.36 (m, 6H), 1.48--1.69 (m, 6H), 1.94 (s, 3H), 2.21--2.30 (m, 1H), 2.35 (q, *J* = 7.1 Hz, 1H), 2.60 (dd, *J* = 4.9, 13.5 Hz, 1H), 2.94 (dd, *J* = 3.3, 13.5 Hz, 1H), 3.00--3.15 (m, 2H), 4.23 (dd, *J* = 3.3, 4.9 Hz, 1H), 6.65 (d, *J* = 2.5 Hz, 1H), 6.96--7.05 (m, 1H), 7.15--7.26 (m, 4H), 7.46--7.55 (m, 3H), 7.88 (d, *J* = 8.2 Hz, 2H), 8.39 (d, *J* = 9.2 Hz, 1H). ^13^C NMR (75 MHz, CDCl~3~): δ 9.8, 28.0, 36.3, 36.4, 38.6, 39.4, 50.6, 62.5, 72.5, 93.0, 125.2, 125.7, 127.2, 127.2, 128.2, 129.3, 129.5, 130.4, 132.2, 132.4, 132.8, 133.8, 136.2, 137.5, 141.7, 169.3, 177.3, 179.2. HRMS: calcd for C~36~H~38~ClIN~3~NiO~3~ \[M + H\]^+^, 780.1000; found, 780.0981.

Ni(II)/(*S*)-**11**/(*R*)-2-Amino-3-(4-nitrophenyl)propanoic Acid Schiff Base Complex (*S*~C~,*R*~N~,*R*~C~)-**15f** {#sec4.9}
--------------------------------------------------------------------------------------------------------------------

Yield: 56.5%. \[α\]~D~^25^ −2237 (*c* 0.058, CHCl~3~). ^1^H NMR (300 MHz, CDCl~3~): δ 1.31 (d, *J* = 7.0 Hz, 3H), 1.20--1.39 (m, 6H), 1.42--1.69 (m, 6H), 1.92 (s, 3H), 2.49--2.66 (m, 2H), 2.88--3.15 (m, 4H), 4.16--4.28 (m, 1H), 6.68 (s, 1H), 6.99 (d, *J* = 6.7 Hz, 1H), 7.16--7.28 (m, 2H), 7.34 (d, *J* = 8.1 Hz, 2H), 7.46--7.62 (m, 3H), 8.23 (d, *J* = 8.1 Hz, 2H), 8.45 (d, *J* = 9.2 Hz, 1H). ^13^C NMR (75 MHz, CDCl~3~): δ 10.0, 28.4, 36.8, 39.2, 40.5, 51.0, 63.8, 71.9, 123.8, 125.4, 126.3, 127.7, 127.8, 128.3, 129.9, 130.1, 131.0, 132.1, 132.8, 133.3, 142.2, 144.2, 148.1, 170.6, 177.8, 179.2. HRMS: calcd for C~36~H~38~ClN~4~NiO~5~ \[M + H\]^+^, 699.1884; found, 699.1882.

Ni(II)/(*S*)-**11**/(*R*)-2-Amino-3-(naphthalen-2-yl)propanoic Acid Schiff Base Complex (*S*~C~,*R*~N~,*R*~C~)-**15g** {#sec4.10}
----------------------------------------------------------------------------------------------------------------------

Yield: 88.1%. \[α\]~D~^25^ −2412 (*c* 0.046, CHCl~3~). ^1^H NMR (300 MHz, CDCl~3~): δ 0.96 (s, 6H), 1.10 (d, *J* = 7.1 Hz, 3H), 1.34--1.63 (m, 8H), 1.82 (s, 3H), 2.16 (q, *J* = 7.1 Hz, 1H), 2.45 (d, *J* = 15.5 Hz, 1H), 2.80 (dd, *J* = 5.3, 13.5 Hz, 1H), 3.20 (dd, *J* = 3.0, 13.5 Hz, 1H), 4.31 (dd, *J* = 2.9, 5.2 Hz, 1H), 6.68 (d, *J* = 2.5 Hz, 1H), 7.10--7.26 (m, 4H), 7.43--7.61 (m, 5H), 7.86--8.10 (m, 4H), 8.33 (d, *J* = 9.2 Hz, 1H). ^13^C NMR (75 MHz, CDCl~3~): δ 9.9, 28.3, 36.3, 36.8, 38.7, 40.2, 49.9, 62.6, 73.3, 125.6, 126.0, 127.1, 127.2, 127.7, 127.8, 128.0, 128.6, 129.7, 129.9, 130.6, 130.7, 130.8, 132.6, 132.7, 133.2, 133.3, 133.9, 134.5, 142.2, 169.4, 178.2, 179.6. HRMS: calcd for C~40~H~41~ClN~3~NiO~3~ \[M + H\]^+^, 704.2190; found, 704.2193.

Synthesis of Fmoc-(*R*)-*m*-bromo-phenylalanine, (*R*)-**21** {#sec4.11}
-------------------------------------------------------------

To a suspension of (*S*~C~,*R*~N~,*R*~C~)-**15a** (740 mg, 1.01 mmol) in methanol (10 mL) was added 3 N HCl (1.68 mL, 5.04 mmol), and the reaction mixture was heated at 50 °C for 1 h. Upon disappearance of the red color of the starting complex, the reaction mixture was concentrated to give a residue. To the residue were added water (10 mL) and ethyl acetate (10 mL) and then the phases were separated. The organic phase was washed with brine (10 mL), dried over sodium sulfate, and evaporated under vacuum to afford the recycle ligand (*S*)-**4** (488 mg, 99.3%). The aqueous phase was concentrated to give crude AA (*R*)-**20**. The residue was dissolved in water (14 mL) and tetrahydrofuran (THF) (7 mL) to which EDTA disodium salt dihydrate (375 mg, 1.01 mmol) was added, and the reaction mixture was basified with sodium carbonate (214 mg, 2.02 mmol) and sodium bicarbonate (169 mg, 2.02 mmol). To this solution was added a solution of Fmoc-OSu (374 mg, 1.11 mmol) in THF (7 mL) and stirred at rt for 16 h. After evaporation of the organic solvents, the aqueous residue was acidified with 3 N HCl to pH 2 to give a precipitate. The precipitate was filtered and washed with water (20 mL) to afford crude (*R*)-**21**. The crude solid thus obtained was recrystallized from THF/IPE (1:1) and dried at 50 °C to afford (*R*)-**21** (466 mg, 99.1%, 97.1% ee). The spectral data were found to be identical with the commercial enantiopure sample. ^1^H NMR (200 MHz, DMSO-*d*~6~): δ 2.85 (dd, *J* = 10.4, 13.7 Hz, 1H), 3.10 (dd, *J* = 4.4, 13.7 Hz, 1H), 4.02--4.33 (m, 4H), 7.14--7.56 (m, 8H), 7.57--7.77 (m, 3H), 7.88 (d, *J* = 7.3 Hz, 2H). ^13^C NMR (50 MHz, DMSO-*d*~6~): δ 36.1, 46.6, 55.4, 65.6, 120.1, 121.4, 125.1, 125.2, 127.0, 127.6, 128.2, 129.2, 130.2, 131.9, 140.6, 140.6, 141.0, 143.7, 143.7, 155.8, 172.9.

Synthesis of Fmoc-(*R*)-*p*-nitro-phenylalanine, (*R*)-**24** {#sec4.12}
-------------------------------------------------------------

To a suspension of (*S*~C~,*R*~N~,*R*~C~)-**15f** (5 g, 7.14 mmol) in methanol (60 mL) was added 3 N HCl (11.9 mL, 35.7 mmol), and the reaction mixture was heated at 50 °C for 1 h. Upon disappearance of the red color of the starting complex, the reaction mixture was concentrated to give a residue. To the residue were added water (25 mL) and ethyl acetate (50 mL) and then the phases were separated. The organic phase was washed with brine (10 mL), dried over sodium sulfate, and evaporated under vacuum to afford the recycle ligand (*S*)-**4** (2.93 g, 84.1%). To the aqueous phase was added EDTA disodium salt dihydrate (2.66 g, 7.14 mmol), and the reaction mixture was basified with 48% sodium hydroxide to pH 13. After stirring at rt for 10 min, the solution was acidified with 12 N HCl to pH 5.5 to give a precipitate. The precipitate was filtered and washed with water (20 mL) to afford AA (*R*)-**23** (1.30 g, 86.6%). The AA (*R*)-**23** thus obtained was dissolved in water (50 mL) and THF (25 mL), and the reaction mixture was basified with sodium carbonate (1.51 g, 14.3 mmol) and sodium bicarbonate (1.20 g, 14.3 mmol). To this solution was added a solution of Fmoc-OSu (2.41 g, 7.14 mmol) in THF (25 mL) and stirred at rt for 16 h. After evaporation of the organic solvents, the aqueous residue was acidified with 3 N HCl to pH 2 to give a precipitate. The precipitate was filtered and washed with water (50 mL) to afford crude (*R*)-**24**. The crude solid thus obtained was recrystallized from THF/IPE (1:1) and dried at 50 °C to afford (*R*)-**24** (2.59 g, 97.1%, 98.6% ee). The spectral data were found to be identical with the commercial enantiopure sample. ^1^H NMR (200 MHz, DMSO-*d*~6~): δ 3.00 (dd, *J* = 10.9, 13.7 Hz, 1H), 3.24 (dd, *J* = 4.4, 13.7 Hz, 1H), 4.02--4.37 (m, 4H), 7.28 (dddd, *J* = 1.0, 3.2, 7.4, 7.4 Hz, 2H), 7.40 (ddd, *J* = 1.0, 7.4, 7.4 Hz, 2H), 7.54 (d, *J* = 8.6 Hz, 2H), 7.61 (d, *J* = 7.4 Hz, 2H), 7.77 (d, *J* = 8.5 Hz, 1H), 7.88 (d, *J* = 7.4 Hz, 2H), 8.14 (d, *J* = 8.6 Hz, 2H). ^13^C NMR (50 MHz, DMSO-*d*~6~): δ 36.2, 46.6, 54.9, 65.6, 120.2, 123.3, 125.2, 127.1, 127.7, 130.5, 140.7, 140.7, 143.7, 143.8, 146.3, 146.5, 156.0, 172.9.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b01424](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b01424).Chiral high-performance liquid chromatography analysis data, copies of ^1^H and ^13^C NMR spectra, and modified precipitation of complex **15f** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01424/suppl_file/ao8b01424_si_001.pdf))
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